The ATP tour reports the player for an Anti-Doping violation. The player provided an In-Competition urine sample, the analysis indicated the prohibited substances Ephedrine, nandrolene or precursors, stanozolol and metabolites and Clenbuterol. By letter the Player admits to have used the prohibited substances, he used them to cure injuries. The player' s admission means that he accepted the lab report. A hearing before the Anti-doping Tribunal is not required.
Because it is a first offense the award will be a 2-year period of ineligibility commencing on the date of the decision, all competitive results obtained from the date the positive sample was collected through to the date of commencement of the ineligibility period ordered herein are disqualified with all the resulting consequences including forfeiture of computer ranking points and prize money.
ITF 2004 ATP Tour vs David Sebok
Original document
Parameters
- Legal Source
- Decisions International Federations
- Date
- 14 May 2004
- Arbitrator
- McLaren, Richard H.
- Original Source
- International Tennis Federation (ITF)
- Country
- United States of America
- Language
- English
- ADRV
- Adverse Analytical Finding / presence
- Legal Terms
- Admission
- No intention to enhance performance
- Sole Arbitrator
- Sport/IFs
- Tennis (ITF) - International Tennis Federation
- Other organisations
- Association of Tennis Professionals (ATP)
- Laboratories
- Montreal, Canada: Laboratoire de controle du dopage INRS-Institut Armand-Frappier
- Doping classes
- S1. Anabolic Agents
- S6. Stimulants
- Substances
- Clenbuterol
- Ephedrine
- Nandrolone (19-nortestosterone)
- Stanozolol
- Medical terms
- Physical injury
- Date generated
- 10 July 2013
- Date of last modification
- 5 March 2014